about the product
Dosage 200 mg Solid gelatin capsules No. 0, white body, white lid, opaque, cylindrical in shape with hemispherical ends.
The dosage is 400 mg Solid gelatin capsules No. 00 are white in color, blue in color, opaque, cylindrical in shape with hemispherical ends .
The contents of the capsules are powder or a mixture of powder and granules from white to yellowish–white in color. Conglomerates (lumps) are allowed to disintegrate when pressed with a glass rod, and may look like a compacted mass in the shape of a cylinder.
Original product
This product is a fully original Promomed product
On every original product you will see our brand label
Specifications
Name
Esperavir®
Dosage form
CAPSULES
Nosological classification
Antiviral drugs of systemic action
INN
MOLNUPIRAVIR
Dosages
200 mg; 400 mg
ATC code
J05AB18
Active substance
Molnupiravir
Pharmacotherapeutic group
Antiviral drugs
use
The drug ESPERAVIR® is taken orally regardless of food intake.
Capsules should be swallowed whole, without opening, crushing or chewing them, washed down with a sufficient amount of liquid (for example, a glass of water).The use of ESPERAVIR® is possible only under medical supervision.
Dosage regimen
For the treatment of the new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus, the following dosage regimen is recommended in adults:
- 4 capsules of 200 mg or 2 capsules of 400 mg orally 2 times a day (every 12 hours). A single dose is 800 mg. The daily dose is 1600 mg. The duration of the course of treatment is 5 days.
Treatment with ESPERAVIR®️ should be initiated as early as possible after the diagnosis of a new coronavirus infection (COVID-19) and/or within 5 days after the first symptoms of the disease appear.
If the next dose of the drug is missed, if the delay in admission is less than 10 hours from the scheduled intake time, then the missed dose should be taken as soon as possible and the usual dosage regimen should be resumed; if the delay in admission is more than 10 hours, then the missed dose should not be taken, and the next dose should be taken at the usual time. The patient should not take a double dose of the drug to compensate for the missed dose.
Special patient groups Advanced age Dose adjustment of ESPERAVIR® is not required depending on age. Kidney failure Dose adjustment of ESPERAVIR® is not required for patients with renal insufficiency. Liver failure Dose adjustment of ESPERAVIR® is not required for patients with hepatic insufficiency. Children There is no data on the safety and efficacy of ESPERAVIR® in children under 18 years of age.
Help
Package leaflet
Molnupiravir is a prodrug that is metabolized to the ribonucleoside analog N-hydroxycytidine (NHC). NHC is distributed into cells and phosphorylated to form pharmacologically active ribonucleoside triphosphate (NHC-TP).
The mechanism of action of NHC-TP operates through a mechanism known as an error catastrophe during the virus replication process. The incorporation of NHC-TP into viral RNA using the RNA polymerase enzyme leads to the accumulation of errors in the viral genome, resulting in suppression of replication.
Treatment of novel coronavirus infection (COVID-19) of mild or moderate severity in adults, including those with an increased risk of disease progression to severe (see "Special instructions" in the leaflet) and those who do not require additional oxygen therapy.
There are no data on cases of overdose of medications with the active ingredient molnupiravir.
Treatment. In case of overdose with ESPERAVIR®, treatment is recommended based on general supportive measures, including monitoring of the patient's clinical condition. It is expected that hemodialysis will not lead to effective elimination of the active substance of the drug.
Brief description of the security profile
The most common adverse reactions reported during treatment with molnupiravir at a dose of 800 mg every 12 hours for 5 days and for 14 days after taking the last dose of the drug were diarrhea (3%), nausea (2%), dizziness (1%) and headache (1%), which had mild or moderate severity.
Detailed information on all adverse reactions can be found in the leaflet
- Hypersensitivity to molnupiravir or any other component of the medicinal product ESPERAVIR®
Pregnancy or pregnancy planning - Breastfeeding period
- Children under 18 years of age
Clinical studies of drug interactions with molnupiravir have not been conducted. Based on the limited amount of available in vitro data, there were no significant risks of clinically significant drug interactions when taking molnupiravir at a dose of 800 mg every 12 hours for 5 days.
Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
An organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro
Store at a temperature not exceeding 25 ° C in the original packaging (pack). Keep out of reach of children.
2 years. Do not use after the expiration date.
They are available on prescription.
Studies on the effect of ESPERAVIR® on the ability to drive a car have not been conducted. During treatment, you should refrain from driving a car, as well as engaging in potentially dangerous activities that require increased concentration and speed of psychomotor reactions.
our partners
Where to buy
